Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 7/20 | 0.63 |
| ▸ | RET | P07949 | 4/20 | 0.59 |
| ▸ | RIPK2 | O43353 | 8/20 | 0.58 |
| ▸ | ABL1 | P00519 | 6/20 | 0.57 |
| ▸ | EGFR | P00533 | 6/20 | 0.57 |
| ▸ | ABL2 | P42684 | 6/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30180884 | 1.00 | SRC (0.63) | SRCRETRIPK2ABL1EGFR | |
| SCHEMBL20351628 | 0.83 | SRC (0.80) | SRCRIPK2ABL1EGFRABL2 | |
| SCHEMBL30180698 | 0.79 | RET (0.58) | SRCRETRIPK2ABL1EGFR | |
| SCHEMBL23966914 | 0.79 | RET (0.58) | SRCRETRIPK2ABL1EGFR | |
| SCHEMBL23966913 | 0.79 | SRC (0.73) | SRCRETRIPK2ABL1EGFR | |
| SCHEMBL18044541 | 0.78 | SRC (0.81) | SRCRETRIPK2ABL1EGFR | |
| SCHEMBL23966925 | 0.78 | RIPK2 (0.72) | SRCRETRIPK2ABL1EGFR | |
| SCHEMBL28928811 | 0.78 | EGFR (0.71) | SRCRIPK2ABL1EGFRABL2 | |
| SCHEMBL28928810 | 0.78 | EGFR (0.71) | SRCRIPK2ABL1EGFRABL2 | |
| SCHEMBL23966720 | 0.77 | SRC (0.70) | SRCRETRIPK2ABL1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713321-B2 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| CN-115843272-A | Inhibitors of NEK7 kinase | 哈利亚治疗公司 | 2023-03-24 | — | — | CN | disclosed |
| WO-2021242505-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. (US) | 2021-12-02 | — | — | WO | disclosed |
| US-20210355130-A1 | INHIBITORS OF NEK7 KINASE | Halia Therapeutics, Inc. | 2021-11-18 | — | — | US | disclosed |
| US-11161852-B1 | Inhibitors of NEK7 kinase | Halia Therapeutics, Inc. (US) | 2021-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355130-A1 | INHIBITORS OF NEK7 KINASE | NEK7, NEK1, NEK5 | SRC 639/4885RET 726/4885RIPK2 56/4885 |
| US-11713321-B2 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | SRC 639/4885RET 726/4885RIPK2 56/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | SRC 3388/4885RET 3195/4885RIPK2 23/4885 |
| US-11161852-B1 | Inhibitors of NEK7 kinase | NEK7, NEK1, NEK5 | SRC 639/4885RET 726/4885RIPK2 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.